Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.52 |
| ▸ | KDR | P35968 | 10/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.49 |
| ▸ | AURKA | O14965 | 2/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 3/20 | 0.47 |
| ▸ | FLT3 | P36888 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3770474 | 0.84 | EGFR (0.52) | BTKKDRAURKBAURKAKIT | |
| SCHEMBL3756301 | 0.83 | FLT3 (0.52) | KDRAURKBMAPK14TNNI3KFLT3 | |
| SCHEMBL3762938 | 0.82 | RET (0.60) | KDRRIPK1AURKBAURKAMAPK14 | |
| SCHEMBL3767943 | 0.82 | FLT3 (0.53) | KDRMAPK14TNNI3KFLT3RET | |
| SCHEMBL3768314 | 0.79 | EGFR (0.46) | BTKKDRAURKBAURKATNNI3K | |
| SCHEMBL3531165 | 0.77 | EGFR (0.50) | AURKBEGFRRETINCENP | |
| SCHEMBL3765192 | 0.77 | KDR (0.56) | KDRAURKBMAPK14TNNI3KKIT | |
| SCHEMBL3762349 | 0.77 | FLT3 (0.49) | KDRMAPK14TNNI3KFLT3EGFR | |
| SCHEMBL3767827 | 0.77 | CDK8 (0.50) | KDRRIPK1AURKBKITFLT3 | |
| SCHEMBL3762266 | 0.76 | KIT (0.62) | KDRRIPK1AURKBKITFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1809629-B1 | N,N'-diphenyl urea derivatives suitable for the treatment of tumours, eye diseases, inflammation and diseases of the immune system | MERCK PATENT GMBH (DE) | 2012-06-13 | — | — | EP | claimed |
| US-7846927-B2 | N,N′-diphenylurea derivatives suitable as kinase inhibitors | MERCK PATENT GMBH (DE) | 2010-12-07 | — | — | US | claimed |
| US-20070293488-A1 | tyrosine kinase inhibitors such as 1-(2-fluoro-5-trifluoromethylphenyl)-3-[4-(5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-4-ylamino)phenyl]urea, used as antitumor or anticarcinogenic agents or for the treatment of psoriasis, arthritis, retinopathy or dermatitis | MERCK PATENT GMBH (DE) | 2007-12-20 | — | — | US | claimed |
| US-7846927-B2 | N,N′-diphenylurea derivatives suitable as kinase inhibitors | MERCK PATENT GMBH (DE) | 2010-12-07 | — | — | US | disclosed |
| US-20070293488-A1 | tyrosine kinase inhibitors such as 1-(2-fluoro-5-trifluoromethylphenyl)-3-[4-(5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-4-ylamino)phenyl]urea, used as antitumor or anticarcinogenic agents or for the treatment of psoriasis, arthritis, retinopathy or dermatitis | MERCK PATENT GMBH (DE) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293488-A1 | tyrosine kinase inhibitors such as 1-(2-fluoro-5-trifluoromethylphenyl)-3-[4-(5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-4-ylamino)phenyl]urea, used as antitumor or anticarcinogenic agents or for the treatment of psoriasis, arthritis, retinopathy or dermatitis | TIE1, FLT1, FER | BTK 184/4885KDR 6/4885RIPK1 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.